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Abstract
Background: The primary goal of this study is to evaluate the immediate and long-term ef-
fects of percutaneous mitral balloon valvuloplasty (PBMV) on patients with rheumatic mitral 
stenosis (MS) complicated with severe pulmonary hypertension (PH).
Methods: The study population consisted of 85 patients with MS complicated with severe 
PH (systolic pulmonary pressure > 75 mm Hg). PBMV was performed with Inoue balloon 
technique. Clinical and echocardiographic follow-up was scheduled at 6 months and 1 year 
and yearly thereafter.
Results: Mitral valve area (MVA) was increased (pre-PBMV MVA was 1.03 ± 0.21 cm2, 
post-PBMV MVA 1.89 ± 0.34 cm2, p < 0.001) significantly. The mean and the maximum 
transmitral pressure gradient significantly decreased (pre-PBMV mean transmitral gradient 
was 18.47 ± 6.59 mm Hg, post-PBMV 6.84 ± 3.84 mm Hg, p < 0.001, pre-PBMV maximum 
transmitral pressure gradient was 27.6 ± 8.38 mm Hg, post-PBMV 12.68 ± 4.74 mm Hg, 
p < 0.001). Systolic pulmonary artery pressure (SPAP) significantly decreased (pre-PBMV 
89.9 ± 23.38 mm Hg, post-PBMV 54.5 ± 14.6 mm Hg, p < 0.001). Two patients underwent 
surgery due to rupture of anterior mitral leaflet. There was no peri-procedural mortality. The 
procedure time was 29.12 ± 11.37 min. Follow-up duration was 108.2 ± 31.4 months. One 
patient died due to heart failure. One patient underwent re-PBMV and 7 patients mitral valve 
replacement. At the last follow-up, MVA still remained high (1.52 ± 0.34 cm2) and mean 
transmitral pressure gradient was low (9.2 ± 5.7 mm Hg). SPAP was 56.5 ± 20.8 mm Hg 
which was the same as after PBMV.
Conclusions: PBMV in patients with MS with severe PH is an effective therapy with low 
procedure time. However, it is recommended to perform PBMV before developing severe PH. 
(Cardiol J 2016; 23, 2: 184–188)
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Introduction
Percutaneous mitral balloon valvuloplasty 
(PBMV) is an effective therapy in patients with 
symptomatic mitral stenosis (MS) [1–3]. In addi-
tion, PBMV is the best choice for isolated MS with 
favorable morphology [4]. However, long-term 
effects of PBMV in high-risk MS patients includ-
ing severe pulmonary hypertension (PH), low 
ejection fraction, and severe tricuspid regurgita-
tion have infrequently been evaluated. Maoqin et 
al. [5] followed up patients with MS complicated 
mild to severe PH for 24 months. The study has 
demonstrated that PBMV can improve immedi-
ate and long-term outcomes of patients with MS 
complicated by severe PH despite inferior hemo-
dynamic results [5]. The primary goal of this study 
was to evaluate the immediate and long-term (at 
least 5 years) results of PBMV in MS patients with 
severe PH.
Methods
From 1994 to 2010, a total 85 out of 435 pa-
tients were included in the study. The criteria for 
inclusion in the study were defined as MS (mitral 
valve area [MVA] £ 1.2 cm2) with symptoms of 
New York Heart Association (NYHA) functional 
class II to IV complicated by systolic pulmonary 
artery pressure (SPAP) above 75 mm Hg. Patients 
with mitral regurgitation (MR) ≥ grade 3, mode-
rate to severe aortic disease (aortic valve area 
< 1.5 cm2 and maximum aortic velocity > 3.0 m/s, 
or moderate to severe aortic regurgitation accord-
ing to echocardiographic assessment including 
pulsed wave (PW) Doppler mapping technique, jet 
height/left ventricular outflow tract [LVOT] height 
and jet area/LVOT area), known coronary artery 
disease (coronary artery stenosis > 50%), or left 
atrial thrombus were excluded from the study.
Clinical statuses of all patients were deter-
mined by NYHA classification. All patients un-
derwent transthoracic (TTE) and transesopha-
geal (TEE) echocardiographic examination before 
PBMV. TTE control was performed to evaluate 
MVA and other parameters 24 h after PBMV. TTE 
evaluation included Wilkins scoring [6], MVA cal-
culation by both planimetric method (MVA meas-
urement by tracing in the short axis view [7]) and 
pressure half-time method [8], and MR estimation 
(graded as none, mild, moderate or severe by color-
Doppler semiquantitative method) [9]. Clinical 
and echocardiographic follow-up was scheduled at 
6 months and 1 year and yearly thereafter. Follow-up 
period was planned at least 4 years. PBMV was 
performed with the Inoue balloon catheter (Toray 
International America Inc.). Probe patency was 
searched and used in patients with previous patent 
foramen ovale as described in the previous study 
[10]. Ideal balloon size was calculated by the height 
based formula: Balloon size (mm) = (height of 
patient in cm/10) + 10.
PBMV was performed by stepwise or single in-
flation method defined earlier [11]. Hemodynamic 
measurements were repeated after PBMV. Success 
of PBMV was defined as post-PBMV MVA > 1.5 cm2 
or an increase > 50% relative to the baseline value 
with no severe MR.
The study was approved by the local ethical 
committee and all patients gave their informed 
consent.
Statistical analysis
Statistical analysis was performed using SPSS 
10 program. Data are presented as mean ± stan-
dard deviation. A value of p < 0.05 was considered 
significant. Two-paired Student’s t test was used 
for continuous variables and c2 tests for categori-
cal variables.
Results
Most of the patients were female (73, 85.8%) 
with a 34.8 ± 10 years mean age. Out of all patients, 
78.8% with sinus rhythm. Acute procedural success 
rate was 100% in 85 patients. Mean procedure time 
(from puncture of the femoral vein to successful 
PBMV) was 29.12 ± 11.37 min. More than 90% of the 
study population had NYHA III–IV functional capac-
ity. Baseline characteristics are displayed in Table 1.
Table 1. Baseline characteristics.
Parameters Study population (n = 85)
Age [years] 34.8 ± 10
Gender (female) 73 (85.8%)
Wilkins Score 7.89 ± 2
Ejection fraction [%] 64 ± 3.16
Sinus rhythm [%] 67 (78.8%)
NYHA class II 8 (9.4%)
NYHA class III 42 (49.4%)
NYHA class IV 35 (41.1%)
Balloon size 26.9 ± 1.07
Procedure time [min] 29.12 ± 11.37
NYHA — New York Heart Association
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The mean transmitral pressure gradient, SPAP 
and mean pulmonary artery pressure (PAP) and 
pulmonary capillary wedge pressure (PCWP) 
significantly decreased after PBMV. Details of 
invasive measurements before and after PBMV is 
shown in Table 2.
MVA was increased (pre-PBMV MVA was 
1.03 ± 0.21, post-PBMV MVA 1.89 ± 0.34 cm2, 
p < 0.001) significantly. The mean and the maxi-
mum transmitral pressure gradient significantly 
decreased (pre-PBMV mean transmitral gradient 
was 18.47 ± 6.59 mm Hg, post-PBMV 6.84 ± 
± 3.84 mm Hg, p < 0.001; pre-PBMV maximum 
transmitral pressure gradient was 27.6 ± 8.38 mm 
Hg, post-PBMV 12.68 ± 4.74 mm Hg, p < 0.001). 
SPAP significantly decreased (pre-PBMV 80.9 ± 
± 23.38 mm Hg, post-PBMV 54.5 ± 14.6 mm Hg, 
p < 0.001). The echocardiographic data are shown in 
Table 3 and echocardiographic follow-up in Table 4. 
Eighty-eight percent of patients were followed 
at the end of the study. Mitral valve replacement 
was needed due to severe MR in 2 patients due to 
rupture of anterior leaflet of mitral valve.
Major adverse cardiac events. Mean follow-
up duration was 108.2 ± 31.4 months. Eighty-
-eight percent of all patients were followed-up 
successfully. During the follow-up period the 
events were:
Death. One patient died due to Lutembacher 
syndrome.
Mitral valve replacement. Seven (8.23%) 
patients underwent surgical therapy indicated by: 
Table 2. Hemodynamic measurements before and after percutaneous balloon mitral valvuloplasty 
(PBMV).
Pre-PBMV Post-PBMV P
Systolic pulmonary artery pressure [mm Hg] 93.27 ± 18.35 57.09 ± 18.82 < 0.001
Mean pulmonary artery pressure [mm Hg] 57.29 ± 11.46 33.72 ± 12.94 < 0.001
Mean mitral gradient [mm Hg] 23.34 ± 5 4.42 ± 3.21 < 0.001
Pulmonary capillary wedge pressure [mm Hg] 32.43 ± 6.76 13.81 ± 7.53 < 0.001
Table 3. Echocardiographic measurements before and after percutaneous balloon mitral valvuloplasty 
(PBMV).
Pre-PBMV Post-PBMV P
Ejection fraction [%] 64 ± 3.16 64.8 ± 4.22 NS
Left atrium [cm] 4.73 ± 0.52 4.47 ± 0.5 < 0.001
SPAP [mm Hg] 89.94 ± 23.28 54.58 ± 14.67 < 0.001
MVA (planimetric method) [cm2] 1.03 ± 0.21 1.89 ± 0.34 < 0.001
MVA (PHT method) [cm2] 1.04 ± 0.23 1.91 ± 0.33 < 0.001
Mean TG [mm Hg] 18.47 ± 6.59 6.84 ± 3.84 < 0.001
Maximum TG [mm Hg] 27.6±8.38 12.68 ± 4.74 < 0.001
MVA — mitral valve area; NS — non-significant; SPAP — systolic pulmonary artery pressure; PHT — pressure half-time; TG — transmitral 
gradient
Table 4. Echocardiographic follow-up.
Pre-PBMV Post-PBMV First year Second year Last follow-up
MVA (planimetric method) 
[cm2]
1.03 ± 0.21 1.89 ± 0.34 1.81 ± 0.3 1.79 ± 0.3 1.53 ± 0.37
Mean transmitral gradient 
[mm Hg]
18.47 ± 6.59 6.84 ± 3.84 7.0 ± 3.1 8.4 ± 4.3 9.2 ± 5.7
SPAP [mm Hg] 80.94 ± 23.28 54.58 ± 14.67 51.9 ± 17 53.2 ± 20.3 55.7 ± 20.6
Left atrium [cm] 4.73 ± 0.52 4.47 ± 0.5 4.31 ± 0.6 4.39 ± 0.5 4.45 ± 0.54
MVA — mitral valve area; PBMV — percutaneous balloon mitral valvuloplasty; SPAP — systolic pulmonary artery pressure
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MR in 1, combination of progressive aortic valve 
disease in 3 and restenosis in 3.
Repeat PBMV: One (1.17%) patient under-
went repeated PBMV.
Discussion
Pulmonary hypertension is a frequent com-
plication of MS. The main mechanism responsible 
for the development of PH is passive retrograde 
transmission of elevated left atrial-pulmonary ve-
nous pressure into pulmonary arterial vasculature. 
Pulmonary venous hypertension induces reactive 
pulmonary arteriolar vasoconstriction [12].
Previous studies have shown that successful 
balloon valvotomy decreased the pulmonary sys-
tolic pressure and the pulmonary vascular resist-
ance to normal or near-normal values in patients 
with mild PH [13–16].
ACC/AHA/ESC guidelines recommend PBMV 
in symptomatic patients with MS and asymptomatic 
patients with high PAP (at rest > 50 mm Hg) as 
well. However, there are limited data about the 
symptomatic patients complicated with PH. This 
group of patients is usually accompanied by moder-
ate to severe tricuspid insufficiency with impaired 
functional capacity and may represent delayed for 
interventional therapy.
Maoquin et al. [5] compared two groups of 
patients with PH > 80 mm Hg and < 50 mm Hg 
according to PAP. These patients were followed for 
24 months. In this study, in the group with severe 
PAP, PAP decreased from 97.8 ± 21.5 mm Hg 
to 54.8 ± 5.8 mm Hg after PBMV. Maoquin et 
al. [5] reported good clinical response despite low 
hemodynamic results.
In our study, SPAP decreased similarly af-
ter PBMV from 89.9 ± 23.38 mm Hg to 54.5 ± 
± 14.6 mm Hg. Unlike the previous study, our 
follow-up period is 108.2 ± 31.4 months. During 
the follow-up period, PAP decreased immediately 
after the procedure and made a plateau value. At 
the end of the follow-up period, the PAP remained 
high when the MVA was 1.52 ± 0.34 cm2. We cal-
culated the value 55.7 ± 20.6 mm Hg at the end.
Cruz-Gonzales et al. [17] studied the effect of 
pulmonary vascular resistance (PVR) on outcomes 
of PBMV in 2013. Two hundred and sixty-three of 
926 patients had elevated PVR (≥ 4 Woods unit). 
The mean PAP in patients with elevated PVR was 
49.17 ± 13.59 mm Hg pre-procedure and signifi-
cantly decreased after PBMV (38.24 ± 12.55 mm 
Hg).They declared that PVR is not an indepen-
dent predictor of procedural success or long-term 
results. Selected patients with rheumatic mitral 
stenosis might benefit from PBMV despite the 
presence of elevated pre-procedural PVR. In our 
study, we did not calculate the PVR, however 
we used PAP. Hemodynamically, pre-PBMV the 
mean PAP was 57.29 ± 11.46 mm Hg and 33.72 ± 
± 12.94 mm Hg after procedure, respectively. The 
mean PAP was significantly higher in our study 
population. When we evaluated the echocardio-
graphic parameters, pre-PBMV SPAP was 89.94 ± 
± 23.28 mm Hg which was significantly decreased 
after the procedure (54.58 ± 14.67 mm Hg) and 
remained high at the last follow-up period (55.7 ± 
± 20.6 mm Hg). Our findings showed that high 
pre-procedural PAP did not affect the procedural 
success as stated by results by Cruz-Gonzales 
et al. [17]. However, at the end of the follow-up 
period, SPAP remained high. These findings sug-
gest that performing PBMV before high PAP may 
improve functional capacity. Therefore, we think 
we should not wait until severe PH developed in 
patients with rheumatic MS for PBMV. However, 
larger multicenter studies are needed to clarify 
this hypothesis.
These results confirm that PAP increases 
during the natural course of mitral stenosis and 
becomes irreversible after a certain value. There-
fore, we suggest that if PBMV is performed before 
severe PH develops, it may prevent irreversible 
changes in the pulmonary vascular bed.
Conclusions
The present study demonstrated excellent 
immediate results of PBMV in patients with 
symptomatic MS complicated by severe PH with 
a lower procedure time. Long-term results were 
comparable with previous studies. However, we 
recommended performing PBMV before develop-
ing severe PH. Further larger multicenter studies 
are needed for clarifying this hypothesis.
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